How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Danofloxacin (CAS 112398-08-0) Market
- By Formulation Type: Injectable Solution, Oral Suspension, Premix
- By Application: Cattle, Swine, Poultry, Aquaculture
- By End-Use: Veterinary Hospitals, Animal Farms, Veterinary Clinics
- By Distribution Channel: Direct Sales, Veterinary Distributors, Online Veterinary Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Injectable Solution leads By Formulation Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.159 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.167 →
Full report · locked preview
Everything inside the Danofloxacin (CAS 112398-08-0) Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Formulation Type 3
Application 4
End-Use 3
Distribution Channel 3
Companies profiled
Zoetis Inc.
Elanco Animal Health Incorporated
Bayer AG
Ceva Santé Animale
Virbac
Merial (now part of Boehringer Ingelheim)
Phibro Animal Health Corporation
Vetoquinol SA
Huvepharma
Norbrook Laboratories Ltd
Jiangsu Hengrui Medicine Co. Ltd.
Shandong Qidu Pharmaceutical Co. Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Elanco Animal Health Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Ceva Santé Animale
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Virbac
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Merial (now part of Boehringer Ingelheim)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Phibro Animal Health Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Vetoquinol SA
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Huvepharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Norbrook Laboratories Ltd
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Shandong Qidu Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Hebei Veyong Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Zhejiang Huahai Pharmaceutical Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,010M by 2033 · 9.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Injectable Solution51.9
- Oral Suspension14.9
- Premix33.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,714M → $3,920M · 10.9%
Europe$1,195M → $2,398M · 9.1%
Asia Pacific$1,091M → $2,104M · 8.6%
Latin America$675.4M → $1,273M · 8.2%
Middle East and Africa$519.5M → $1,135M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.792026
9.812027
9.822028
9.832029
9.832030
9.862031
9.862032
9.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zoetis Inc.25.6
- Elanco Animal Health Incorporated20.8
- Bayer AG6.5
- Ceva Santé Animale4.6
- Virbac4.2
- Merial (now part of Boehringer Ingelheim)10.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Formulation Type35.4%
Application26.5%
End-Use17.8%
Distribution Channel20.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America36.2
- Europe22.1
- Asia Pacific19.4
- Latin America11.8
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. | 85 | 78 | 94 | 77 | 93 | 84 | 85 |
| Elanco Animal Health Incorporated | 78 | 70 | 80 | 68 | 86 | 90 | 79 |
| Bayer AG | 72 | 74 | 66 | 81 | 73 | 82 | 75 |
| Ceva Santé Animale | 62 | 60 | 81 | 69 | 59 | 68 | 67 |
| Virbac | 75 | 57 | 75 | 74 | 66 | 75 | 70 |
| Merial (now part of Boehringer Ingelheim) | 50 | 68 | 50 | 56 | 61 | 53 | 56 |
| Phibro Animal Health Corporation | 56 | 49 | 44 | 52 | 47 | 65 | 52 |
| Vetoquinol SA | 59 | 37 | 49 | 58 | 41 | 43 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zoetis Inc.
- Elanco Animal Health Incorporated
- Bayer AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zoetis Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Elanco Animal Health Incorporated | ◐ | ◐ | ✓ | − | ✓ | ◐ |
| Bayer AG | ◐ | ✓ | ◐ | ✓ | ◐ | ✓ |
| Ceva Santé Animale | ◐ | − | ✓ | ◐ | ◐ | ✓ |
| Virbac | ◐ | − | ◐ | ◐ | ◐ | ◐ |
| Merial (now part of Boehringer Ingelheim) | − | ✓ | − | − | ◐ | − |
| Phibro Animal Health Corporation | ◐ | − | − | − | ◐ | ◐ |
| Vetoquinol SA | ◐ | − | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zoetis Inc.85
2Elanco Animal Health Incorporated79
3Bayer AG75
4Virbac70
5Ceva Santé Animale67
6Merial (now part of Boehringer Ingelheim)56
7Phibro Animal Health Corporation52
8Vetoquinol SA48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Zoetis Inc.Elanco Animal Health Incorporated
Challenger3
Strong scale, closing on the leaders.
Bayer AGCeva Santé AnimaleVirbac
Niche3
Specialists in a single segment or region.
Merial (now part of Boehringer Ingelheim)Phibro Animal Health CorporationVetoquinol SA
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Formulation Type in North America, then scale across Danofloxacin (CAS 112398-08-0) Market — a $564M beachhead inside a $7.91B market.
Beachhead (SOM)$564Mobtainable near-term
Serviceable (SAM)$3.27Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Injectable Solution
Best fit — highest urgency & budget in Formulation Type.
Economic buyer81 fit
Oral Suspension
Strong fit — clear ROI and a fast path to value.
End user65 fit
Premix
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Formulation Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-Use
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve19%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Formulation Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Danofloxacin (CAS 112398-08-0) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified25%
Evaluation15%
Closed-won6%
$8.8KCAC
$41KLTV
4.6:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Danofloxacin (CAS 112398-08-0) Market is a durable-growth opportunity — $8.44B by 2033, compounding at 6.4%.
TAM · 2025$5.14Btoday
TAM · 2033$8.44Bforecast
CAGR6.4%2027–2033
Cumulative$60.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.44BTotal addressable market
SAM$3.19BServiceable available market
SOM$582MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.4% CAGR
Demand compounds through 2033, outpacing GDP across Formulation Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Formulation Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.44BLarge & growingTAM by 2033 at 6.4% CAGR
$3.19BServiceable nowreachable with today’s model
$582MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.58BBear4.2% CAGR
$8.44BBase6.4% CAGR
$10.8BBull8.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Danofloxacin (CAS 112398-08-0) Market — a $3.95B market by 2033. Plan: grow share from 6.8% to 13.5%.
Market size · 2033$3.95Btotal addressable
Market CAGR5.1%2027–2033
Target share13.5%from 6.8% today
Revenue ambition$534Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.8% | 13.5% | At risk |
| Revenue | $244M | $534M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 31.9% | 43.2% | On track |
| Customer retention | 91.5% | 96.4% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Formulation Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Formulation Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $62M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Formulation Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Danofloxacin (CAS 112398-08-0) Market conversation — a $1.14B market you can size, segment and defend in minutes.
Market size · 2033$1.14Btotal opportunity
Growth9.2%CAGR to 2033
Addressable buyers1,620+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Formulation Type
Goal Grow share in Formulation Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 3 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Zoetis Inc.Elanco Animal Health IncorporatedBayer AGCeva Santé AnimaleVirbacMerial (now part of Boehringer Ingelheim)Phibro Animal Health CorporationVetoquinol SA+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Danofloxacin (CAS 112398-08-0) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Danofloxacin (CAS 112398-08-0) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Spectinomycin (CAS 1695-77-8) Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportKitasamycin (CAS 69-23-8) Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportYeast Expression Vector Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportXylitol in Pharmaceutical Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportTumor Necrosis Factor Receptor Superfamily Member 9 Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportTumor Necrosis Factor Inhibitors Drug Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportThymosin Alpha-1 Market
Market size, share, segmentation and regional forecast.
$769M market · 2025 base year
View reportThymic Carcinoma Treatment Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportThrombopoietin Receptor Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportRadicava Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportRadiation Injury Drugs Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportProtein Phosphatase 2A Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.